- Home
- INO
as 07-26-2024 4:00pm EST
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 240.5M | IPO Year: | 1998 |
| Target Price: | $19.60 | AVG Volume (30 days): | 552.6K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.84 - $14.75 | Next Earning Date: | 08-07-2024 |
| Revenue: | $717,068 | Revenue Growth: | -92.95% |
| Revenue Growth (this year): | -57.73% | Revenue Growth (next year): | 5587.45% |
Latest Inovio Pharmaceuticals Inc. News
INO Breaking Stock News: Dive into INO Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
PR Newswire
a day ago
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
Zacks
14 days ago
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
Zacks
14 days ago
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?
PR Newswire
15 days ago
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway
MT Newswires
24 days ago
Inovio Pharmaceuticals Names Steven Egge Chief Commercial Officer
PR Newswire
24 days ago
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
PR Newswire
25 days ago
INOVIO Reports Inducement Grant Under Inducement Plan
Compare INO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INO Inovio Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.